Association of primary Sjogren's syndrome with incident heart failure: a secondary analysis of health claims data in Taiwan

CNU IR > Pharmacy and Science > Dept. of Pharmacy > Periodical Articles > Item 310902800/34705

Please use this identifier to cite or link to this item: https://ir.cnu.edu.tw/handle/310902800/34705

Title:	Association of primary Sjogren's syndrome with incident heart failure: a secondary analysis of health claims data in Taiwan
Authors:	Lin, Chun-Yu Chen, Hung-An Chang, Tsang-Wei Hsu, Tsai-Ching Hsu, Chung-Yuan Su, Yu-Jih
Contributors:	Chang Gung Memorial Hospital Chang Gung University National Cheng Kung University National Cheng Kung University Hospital Chi Mei Hospital Chia Nan University of Pharmacy & Science National Cheng Kung University National Cheng Kung University Hospital Chung Shan Medical University
Keywords:	chronic inflammatory diseases risk classification pathogenesis pilocarpine mortality criteria markers burden cells
Date:	2022
Issue Date:	2023-12-11 14:06:11 (UTC+8)
Publisher:	SAGE PUBLICATIONS LTD
Abstract:	Objective: Mounting evidence has demonstrated that various chronic inflammatory diseases are associated with incident heart failure (HF). However, there is scarce evidence about the association between primary Sjogren's syndrome (pSS) and HF. We aimed to explore this association using a nationwide database in Taiwan. Methods: We selected patients with incident pSS and no history of HF. Using propensity score matching based on age, sex, cohort entry time, comorbidities, and concomitant medications, cohorts of patients with and without pSS (as controls) were created in a 1:1 ratio and the groups were compared. The cumulative incidence of HF was calculated using Kaplan-Meier estimation. Cox proportional hazard regression analysis was used to measure the hazard ratio (HR) of HF-related hospitalization for the pSS cohort compared with the comparison group. Results: A total of 16,466 pairs of patients with pSS and those without pSS were identified. The cumulative incidence of HF-related hospitalization at 3, 5, and 10years in patients with pSS was 1.05%, 1.89%, and 4.33%, respectively. The risk of HF-related hospitalization was not higher in patients with pSS than in the general population (HR: 0.98, 95% confidence interval [CI]: 0.84-1.14). There was no difference in survival probability after the first episode of HF-related hospitalization between pSS and non-pSS groups. Conclusion: Our results suggest that distinct inflammatory spectrums in each chronic inflammatory disease might have differential impacts on cardiac function and subsequent risk of HF. Future studies are needed to elucidate the complex and diverse mechanisms of HF in various chronic autoimmune diseases.
Relation:	Therapeutic Advances in Chronic Disease, v.13, pp.1-11
Appears in Collections:	[Dept. of Pharmacy] Periodical Articles

Files in This Item:

File	Description	Size	Format
20406223221078083.pdf		422Kb	Adobe PDF	100	View/Open
index.html		0Kb	HTML	191	View/Open

Loading...